Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Scientists say they may have discovered a natural version of Ozempic that can replicate the effects of popular weight loss ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

Gillian Killiner RD, a specialist dietician at 121 Dietician, told The Independent: “Alternatives to GLP-1 medications like Ozempic, can be achieved using a holistic, evidence-based approach ...

A government crackdown on cheaper copies of Ozempic and similar diabetes and weight-loss drugs was intended to shut the door on that booming market ... less-expensive alternatives not approved ...